NASDAQ: SLP
Simulations Plus Inc Stock Forecast, Predictions & Price Target

Analyst price target for SLP

Based on 1 analyst offering 12 month price targets for Simulations Plus Inc

Min Forecast
$16.00-0.37%
Avg Forecast
$16.00-0.37%
Max Forecast
$16.00-0.37%

Should I buy or sell SLP stock?

Based on 1 analyst offering ratings for Simulations Plus Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their SLP stock forecasts and price targets.

SLP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-10

1 of 1

Forecast return on equity

Is SLP forecast to generate an efficient return?

Company
19.53%
Industry
23.22%
Market
162.36%
SLP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SLP forecast to generate an efficient return on assets?

Company
17.83%
Industry
17.03%
SLP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SLP earnings per share forecast

What is SLP's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.42
Avg 2 year Forecast
$0.47
Avg 3 year Forecast
$1.11

SLP revenue forecast

What is SLP's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$82.4M+2.32%
Avg 2 year Forecast
$87.3M+8.37%
Avg 3 year Forecast
$99.0M+22.94%
SLP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SLP revenue growth forecast

How is SLP forecast to perform vs Health Information Services companies and vs the US market?

Company
6.26%
Industry
8.63%
Market
14.05%
SLP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SLP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SLP vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
SLP$16.06$16.00-0.37%Hold
SY$3.02N/AN/A
SOPH$5.40$7.50+38.89%Strong Buy
CARL$9.75$19.33+98.29%Strong Buy
TBRG$25.78$23.38-9.33%Hold

Simulations Plus Stock Forecast FAQ

Is Simulations Plus Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SLP) stock is to Hold SLP stock.

Out of 1 analyst, 0 (0%) are recommending SLP as a Strong Buy, 0 (0%) are recommending SLP as a Buy, 1 (100%) are recommending SLP as a Hold, 0 (0%) are recommending SLP as a Sell, and 0 (0%) are recommending SLP as a Strong Sell.

If you're new to stock investing, here's how to buy Simulations Plus stock.

What is SLP's earnings growth forecast for 2026-2028?

(NASDAQ: SLP) Simulations Plus's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 26.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.

Simulations Plus's earnings in 2026 is -$62,787,000.On average, 8 Wall Street analysts forecast SLP's earnings for 2026 to be $8,571,165, with the lowest SLP earnings forecast at $7,524,521, and the highest SLP earnings forecast at $9,334,933. On average, 8 Wall Street analysts forecast SLP's earnings for 2027 to be $9,547,090, with the lowest SLP earnings forecast at $7,722,535, and the highest SLP earnings forecast at $11,224,145.

In 2028, SLP is forecast to generate $22,448,291 in earnings, with the lowest earnings forecast at $21,781,510 and the highest earnings forecast at $23,337,332.

What is SLP's revenue growth forecast for 2026-2028?

(NASDAQ: SLP) Simulations Plus's forecast annual revenue growth rate of 6.26% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 8.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.05%.

Simulations Plus's revenue in 2026 is $80,535,000.On average, 8 Wall Street analysts forecast SLP's revenue for 2026 to be $1,665,052,950, with the lowest SLP revenue forecast at $1,594,010,475, and the highest SLP revenue forecast at $1,750,299,878. On average, 8 Wall Street analysts forecast SLP's revenue for 2027 to be $1,763,453,647, with the lowest SLP revenue forecast at $1,675,196,102, and the highest SLP revenue forecast at $1,870,603,318.

In 2028, SLP is forecast to generate $2,000,463,951 in revenue, with the lowest revenue forecast at $1,847,468,041 and the highest revenue forecast at $2,179,969,453.

What is SLP's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SLP) forecast ROA is 17.83%, which is higher than the forecast US Health Information Services industry average of 17.03%.

What is SLP's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SLP price target, the average SLP price target is $16.00, with the highest SLP stock price forecast at $16.00 and the lowest SLP stock price forecast at $16.00.

The Wall Street analyst predicted that Simulations Plus's share price could fall to $16.00 by Apr 10, 2027. The average Simulations Plus stock price prediction forecasts a potential downside of 0.37% from the current SLP share price of $16.06.

What is SLP's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SLP) Simulations Plus's current Earnings Per Share (EPS) is -$3.13. On average, analysts forecast that SLP's EPS will be $0.42 for 2026, with the lowest EPS forecast at $0.37, and the highest EPS forecast at $0.46. On average, analysts forecast that SLP's EPS will be $0.47 for 2027, with the lowest EPS forecast at $0.38, and the highest EPS forecast at $0.56. In 2028, SLP's EPS is forecast to hit $1.11 (min: $1.08, max: $1.16).

What is SLP's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SLP) forecast ROE is 19.53%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.